Search

BACKGROUND:AML is an aggressive malignancy primarily affecting older individuals. Although 40%-60% of patients (pts) aged >60 years attain complete remission (CR) with IC, 80%-90% of them eventually relapse. In the continuum of AML care, the greatest expenditures are associated with relapsed/refractory disease, and hospitalization is the largest component (~70%) of direct AML healthcare costs (Pandya, 2020).

Introduction: Doublet combinations including lenalidomide (len) and dexamethasone (dex; Ld) are increasingly used to treat frontline (FL) multiple myeloma (MM) patients (pts). Len has also been used as maintenance therapy where strategies increasing len dose with first relapse have been considered (Harousseau JL et al. Blood2017). Triplet combinations are emerging as standard of care for relapsed/refractory (RR) MM and the treatment paradigm is shifting, with new agents like carfilzomib, ixazomib, elotuzumab, and daratumumab being added to Ld. Although these new combinations have shown improved clinical outcomes in RRMM, most pts ultimately relapse. Thus, treatment decision with each relapse becomes increasingly important to improve survival; the most critical decision may come at first relapse. With earlier len use, better understanding of treatment sequencing patterns of len and its use in clinical practice settings may help optimize treatment strategies in RRMM pts in later lines. We present real-world clinical practice data on treatment sequencing at relapse from len-based FL therapy.

Introduction: Many new treatments and combinations have emerged over the last decade to treat relapsed or refractory multiple myeloma (RRMM). Treatment strategies include doublet and/or triplet combinations from the following classes of agents: immunomodulatory drugs, proteasome inhibitors, and recently approved immuno-oncology agents. Combinations with new agents like pomalidomide, carfilzomib, ixazomib, elotuzumab, and daratumumab have demonstrated improved survival in RRMM in clinical trials, specifically with continued treatment until disease progression, with an acceptable safety profile (Lonial S et al. N Engl J Med2015; Dimopoulos M et al. N Engl J Med2016; Palumbo A et al. N Engl J Med2016; Moreau P et al. N Engl J Med2016; Stewart AK et al. N Engl J Med2015; Dimopoulos M et al. Blood2012). Median duration of treatment (DoT) was described in the literature as 12.4 wk for pomalidomide plus low-dose dexamethasone, 68 wk for ixazomib plus lenalidomide/dexamethasone, 74 wk for elotuzumab plus lenalidomide/dexamethasone, and 88 wk for carfilzomib plus lenalidomide/dexamethasone (Lonial S et al. N Engl J Med2015; Moreau P et al. N Engl J Med2016; Stewart AK et al. N Engl J Med2015; Dimopoulos M et al. Blood2012). The actual DoT of these agents in clinical practice settings is not known and it is unclear if DoT is affected by safety concerns and/or might have an impact on patient (pt) outcomes. Here we provide real-world evidence of DoT and time to next therapy (TTNT) with each of these agents in an attempt to understand their potential for durability of response and tolerability.

Lenihan: BMS, Roche, Amgen (Consultancy); Takeda (Research Funding): Consultancy, Research Funding. Potluri:Janssen Research & Development, LLC: Other: Contracted to perform research; SmartAnalyst, Inc.: Employment. Bhandari:SmartAnalyst India Pvt. Ltd.: Employment. Ranjan:SmartAnalyst India Pvt. Ltd.: Employment. Chen:Bristol-Myers Squibb: Employment.

Potluri: Janssen Research & Development, LLC: Other: Contracted to perform research; SmartAnalyst, Inc.: Employment. Bhandari:SmartAnalyst India Pvt. Ltd.: Employment. Ranjan:SmartAnalyst India Pvt. Ltd.: Employment. Chen:Bristol-Myers Squibb: Employment.

Background:Multiple myeloma (MM) is typically diagnosed in older adults, with a median age at diagnosis of 69 years and the majority diagnosed between ages 65 and 74 years. It might be expected that cardiovascular disease (CVD) would be common in this patient population but currently there is little data about CVD in this population. CVD events may be consequences of age-related comorbidities, CVD itself, or anti-MM treatment received. Anthracycline chemotherapy, certain proteasome inhibitors and immunomodulatory drugs have been reported to increase the risk of CVD complications.

Background:Despite advances in the treatment of multiple myeloma (MM), patients with this high-burden disease continue to be at an high risk of relapse and progression. This underscores the considerable unmet need for new agents that can provide durable disease control in patients with relapsed/refractory MM (RRMM). Elotuzumab is a SLAMF7-directed immunostimulatory antibody recently approved by the US Food and Drug Administration, in combination with lenalidomide and dexamethasone (ELd), for the treatment of patients with MM who have received 1-3 prior therapies. This approval was based on the results from ELOQUENT-2, a randomized, open-lable, Phase 3 study, showing a 30% reduction in the risk of disease progression or death with minimal additional toxicity, over the combination of lenalidomide and dexamethasone.